Bispecific Antibodies in Targeted Cancer Immunotherapy
- 26 January 2023
- book chapter
- Published by Springer Nature
- p. 1-46
Abstract
No abstract availableKeywords
This publication has 198 references indexed in Scilit:
- Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast CancerMolecular & Cellular Proteomics, 2013
- Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaCochrane Database of Systematic Reviews, 2012
- Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodiesProtein Engineering, Design and Selection, 2011
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell DepletionJournal of Molecular Biology, 2010
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- Prostate stem cell antigen: A prospective therapeutic and diagnostic targetCancer Letters, 2009
- Elevated levels of HER‐2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potentialThe Prostate, 2008
- A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cellsCancer Immunology, Immunotherapy, 2007
- Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemiaInternational Immunology, 2006
- ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerizationProtein Engineering, Design and Selection, 1996